GILEAD SCIENCES INC Form 8-K December 18, 2017

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

### FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Rer	ort (Date of Earliest Event Re	enorted):	December 14, 20	117
Date of Rep	of (Date of Larnest Event Ne	ported).	December 14, 20	11 /

# Gilead Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware	0-19731	94-3047598  (I.R.S. Employer Identification No.)	
(State or other jurisdiction of incorporation)	(Commission File Number)		
333 Lakeside Drive, Foster City, California		94404	
(Address of principal executive offices)		(Zip Code)	
Registrant s telephone number, including a	650-574-3000		
	Not Applicable		
Former name	e or former address, if changed since l	ast report	
Check the appropriate box below if the Form 8-K filing the following provisions:	g is intended to simultaneously satisfy	the filing obligation of the registrant under any of	
[ ] Written communications pursuant to Rule 425 under [ ] Soliciting material pursuant to Rule 14a-12 under to Pre-commencement communications pursuant to R [ ] Pre-commencement communications pursuant to R	the Exchange Act (17 CFR 240.14a-12 Lule 14d-2(b) under the Exchange Act	2) (17 CFR 240.14d-2(b))	

### Top of the Form



Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

#### Top of the Form

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Transition of Executive Chairman to Chairman of the Board of Directors

On December 14, 2017, Gilead Sciences, Inc., a Delaware corporation (the "Company"), announced that John C. Martin, Ph.D., the Company's Executive Chairman, will transition from his position as Executive Chairman to Chairman of the Board of Directors effective March 9, 2018.

A copy of the Company's press release is attached as Exhibit 99.1 to this report.

#### Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibit

Number Description

99.1 Press Release, issued by Gilead Sciences, Inc. on December 14, 2017.

### Top of the Form

### Exhibit Index

Exhibit No.	Description
99.1	Press Release, issued by Gilead Sciences, Inc. on December 14, 2017

### Top of the Form

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Gilead Sciences, Inc.

December 15, 2017 By: /s/ Brett A. Pletcher

Name: Brett A. Pletcher

Title: EVP, General Counsel and Corporate Secretary

### Top of the Form